The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE

The Gross Law Firm has alerted shareholders of uniQure N.V. (NASDAQ: QURE) regarding an important lead plaintiff deadline related to a class action lawsuit. Investors who purchased shares between September 24, 2025, and October 31, 2025, are encouraged to contact the firm for potential lead plaintiff appointment. This appointment is not necessary for participation in any recovery from the lawsuit.

The lawsuit alleges that uniQure's executives made materially false and misleading statements during the class period. Specifically, it accuses them of failing to disclose that the design of their Pivotal Study had not received full FDA approval and of downplaying the potential delays in the company's Biologics License Application (BLA) caused by the need for additional studies. These omissions allegedly misled investors about the company's operations, business prospects, and overall integrity.

Shareholders are advised to register for the class action before the deadline of April 13, 2026. This registration process is essential for those who wish to stay updated on the case, as it provides them with access to a portfolio monitoring system that will deliver status updates throughout the legal proceedings. Importantly, participating in the case incurs no cost or obligation for shareholders.

The Gross Law Firm, a nationally recognized class action law firm, states its mission as protecting investor rights against deceit and fraudulent activities. They emphasize their commitment to ensuring that companies adhere to ethical practices, advocating for the recovery of losses suffered due to misleading corporate statements.

For further assistance, shareholders can contact The Gross Law Firm directly via phone or email, or visit their website for more information and to submit claims.

The recent communication from The Gross Law Firm regarding the deadline for shareholders of uniQure N.V. (NASDAQ: QURE) to engage in a lead plaintiff role may influence market sentiment and trading strategies around the stock. As shareholders consider their options in light of the allegations—including potentially misleading statements related to the FDA approval process—investors need to approach uniQure with caution.

The allegations mention serious concerns, particularly regarding the FDA approval of the Pivotal Study's design and the impact of additional required studies on the company's timeline for the Biologics License Application (BLA). Such claims, if validated, could lead to significant volatility in stock price. Investors should assess the risks associated with holding shares of QURE as the lawsuit progresses.

For those currently holding shares, it may be prudent to consider potential exit strategies. If the stock shows significant downward pressure as the lawsuit unfolds, selling could mitigate losses. Conversely, for value-oriented investors, this could present a potential buying opportunity if the market reaction overshoots.

For shareholders who purchased shares during the class period from September 24, 2025, to October 31, 2025, engaging with The Gross Law Firm could provide important updates and insights. Registering for the class action, even without pursuing a lead plaintiff role, could help investors stay informed about the case's developments and assess its potential impact on uniQure's market value.

In summary, the upcoming lead plaintiff deadline on April 13, 2026, signals a critical moment for investors. Cautious monitoring and a well-defined strategy could help navigate the risks tied to this litigation while keeping an eye on the company’s operational metrics and developments.